According to BrainScope, its Ahead 300 device will lead to a speedier diagnosis of concussion in sports players, which can currently take up to 30 minutes.
The device was approved by the US Food and Drug Administration (FDA) last year and uses electroencephalography (EEG) capabilities plus algorithms and machine learning to provide a results.
Speaking to the Irish Times company CEO, Michael singer said: “We have created this capability, where there are elements that may already be used by clinicians and we put those on the device in digitised format.”
“We are thrilled to be introducing the Ahead 300 to the market. We strongly believe this medical device represents a paradigm shift in how clinicians will address the multitude of challenges they face when they assess mildly presenting head-injured patients,” continued Singer.
“The Ahead 300 is the first-to-market medical technology capable of providing objective, easily accessible and multimodal information in a panel format for up to three days following injury. As the first line of assessment, the Ahead 300 can have significant impact on helping the clinician make their diagnosis for proper patient disposition.”
“This is a brand new product, a pioneering product,” added Mr Singer. “There’s a group of core clinical sites, all in the US that we are beginning with, hospitals, sport and some others.”